{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:18:44Z","timestamp":1761718724958,"version":"3.41.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CONACYT","award":["CB-254600","CB-235785","PDCPN-782","I010\/0532\/2014"],"award-info":[{"award-number":["CB-254600","CB-235785","PDCPN-782","I010\/0532\/2014"]}]},{"name":"COFAA-SIP\/IPN","award":["20180810"],"award-info":[{"award-number":["20180810"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jpba.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T04:04:36Z","timestamp":1536120276000},"page":"130-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin"],"prefix":"10.1016","volume":"162","author":[{"given":"Ana Mar\u00eda","family":"Correa-Basurto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio","family":"Romero-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Correa-Basurto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricarmen","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6529-1502","authenticated-orcid":false,"given":"Marvin Antonio","family":"Soriano-Urs\u00faa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jazmin","family":"Garc\u00eda-Machorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Esteban","family":"Tolentino-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Cecilia","family":"Rosales-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Elena","family":"Mendieta-Wejebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2018.09.010_bib0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpba.2018.09.010_bib0010","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpba.2018.09.010_bib0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jpba.2018.09.010_bib0020","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2019-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2018.09.010_bib0025","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2018.09.010_bib0030","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2018.09.010_bib0035","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.jpba.2018.09.010_bib0040","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kr\u00e4mer","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.jpba.2018.09.010_bib0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","article-title":"Histone deacetylase inhibitors as new cancer drugs","volume":"13","author":"Marks","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/tera.1420350319","article-title":"Teratogen update: valproic acid","volume":"35","author":"Lammer","year":"1987","journal-title":"Teratology"},{"key":"10.1016\/j.jpba.2018.09.010_bib0055","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1528-1157.1992.tb02355.x","article-title":"Effect of valproate dose on formation of hepatotoxic metabolites","volume":"33","author":"Anderson","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpba.2018.09.010_bib0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2710.1999.00201.x","article-title":"Clinically significant pharmacokinetic drug interactions between antiepileptic drugs","volume":"24","author":"Tanaka","year":"1999","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2018.09.010_bib0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(99)00037-1","article-title":"Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs","volume":"62","author":"Bialer","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jpba.2018.09.010_bib0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00019052-200304000-00014","article-title":"New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?","volume":"16","author":"Isoherranen","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/14756366.2016.1210138","article-title":"N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells","volume":"31","author":"Prestegui-Martel","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"year":"2016","series-title":"Evaluaci\u00f3n hepatot\u00f3xica del derivado de \u00e1cido valproico N-(2-hidroxifenil)-2-propilpentanamida","author":"Correa-Basurto","key":"10.1016\/j.jpba.2018.09.010_bib0080"},{"key":"10.1016\/j.jpba.2018.09.010_bib0085","series-title":"Humane Endpoints in Animal Experimentation for Biomedical Research: Ethical, Legal and Practical Aspects, Human Endpoints in Animal Experiments for Biomedical Research","first-page":"5","author":"Morton","year":"1999"},{"key":"10.1016\/j.jpba.2018.09.010_bib0090","series-title":"Bioanalytical Method Validation. Guidance for Industry","first-page":"1","author":"Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.jpba.2018.09.010_bib0095","series-title":"The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","first-page":"1","article-title":"ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1)","year":"2005"},{"key":"10.1016\/j.jpba.2018.09.010_bib0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/bip.21314","article-title":"Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand\u2013protein interactions","volume":"93","author":"Deeb","year":"2010","journal-title":"Biopolymers"},{"key":"10.1016\/j.jpba.2018.09.010_bib0105","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jpba.2018.09.010_bib0110","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1021\/jp973084f","article-title":"All-atom empirical potential for molecular modeling and dynamics studies of proteins","volume":"102","author":"MacKerell","year":"1998","journal-title":"J. Phys. Chem. B"},{"issue":"33-38","key":"10.1016\/j.jpba.2018.09.010_bib0115","first-page":"27","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.jpba.2018.09.010_bib0120","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1063\/1.467468","article-title":"Constant pressure molecular dynamics algorithms","volume":"101","author":"Martyna","year":"1994","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.jpba.2018.09.010_bib0125","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1063\/1.1389854","article-title":"Optimized particle-mesh Ewald\/multiple-time step integration for molecular dynamics simulations","volume":"115","author":"Batcho","year":"2001","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.jpba.2018.09.010_bib0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"10.1016\/j.jpba.2018.09.010_bib0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"year":"1998","series-title":"Gaussian 98, Revision A.7","author":"Frisch","key":"10.1016\/j.jpba.2018.09.010_bib0140"},{"key":"10.1016\/j.jpba.2018.09.010_bib0145","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"year":"2002","series-title":"The PyMOL Molecular Graphics System","author":"DeLano","key":"10.1016\/j.jpba.2018.09.010_bib0150"},{"key":"10.1016\/j.jpba.2018.09.010_bib0155","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0006-2952(91)90662-O","article-title":"Effect of valproic acid, its unsaturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsarcosine to human albumin","volume":"41","author":"Panjehshahin","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/bip.20058","article-title":"Surface-enhanced Raman spectroscopy study of the interaction of the antitumoral drug emodin with human serum albumin","volume":"74","author":"Fabriciova","year":"2004","journal-title":"Biopolymers"},{"key":"10.1016\/j.jpba.2018.09.010_bib0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.colsurfb.2015.01.023","article-title":"Surface-enhanced Raman spectroscopy of the anti-cancer drug irinotecan in presence of human serum albumin","volume":"127","author":"Vicario","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.jpba.2018.09.010_bib0170","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/bip.21278","article-title":"Spectroscopic and molecular modeling studies on the binding of the flavonoid luteolin and human serum albumin","volume":"91","author":"Jurasekova","year":"2009","journal-title":"Biopolymers"},{"key":"10.1016\/j.jpba.2018.09.010_bib0175","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1006\/jmbi.1994.1017","article-title":"Significance of root-mean-square deviation in comparing three-dimensional structures of globular proteins","volume":"235","author":"Maiorov","year":"1994","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0180","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1134\/S0026893308040195","article-title":"Radius of gyration is indicator of compactness of protein structure","volume":"42","author":"Lobanov","year":"2008","journal-title":"Mol. Biol. (Mosk.)"},{"key":"10.1016\/j.jpba.2018.09.010_bib0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpba.2018.09.010_bib0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drudis.2012.09.004","article-title":"A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery","volume":"18","author":"Li","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpba.2018.09.010_bib0200","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.drudis.2007.10.014","article-title":"Snapshot PK: a rapid rodent in vivo preclinical screening approach","volume":"13","author":"Liu","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpba.2018.09.010_bib0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s13318-011-0066-5","article-title":"A modified serial blood sampling technique and utility of dried-blood spot technique in estimation of blood concentration: application in mouse pharmacokinetics","volume":"37","author":"Kurawattimath","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jpba.2018.09.010_bib0210","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/bmc.3307","article-title":"A simple validated RP-HPLC bioanalytical method for the quantitative determination of a novel valproic acid arylamide derivative in rat hepatic microsomes","volume":"29","author":"Silva-Trujillo","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2018.09.010_bib0215","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0272-0590(88)90112-1","article-title":"Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats","volume":"11","author":"Binkerd","year":"1988","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0220","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/1871520616666160204111158","article-title":"Docking studies of glutamine valproic acid derivative (S)-5-amino-2-(heptan-4-ylamino)-5-oxopentanoic acid (Gln-VPA) on HDAC8 with biological evaluation in HeLa cells","volume":"16","author":"Mart\u00ednez-Ramos","year":"2016","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.jpba.2018.09.010_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apcsb.2015.09.007","article-title":"High-Performance Affinity Chromatography: applications in drug\u2013protein binding studies and personalized medicine","volume":"102","author":"Li","year":"2016","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1528-1157.1979.tb04779.x","article-title":"Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids","volume":"20","author":"Patel","year":"1979","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpba.2018.09.010_bib0235","first-page":"201","article-title":"Displacement effect of valproate on bilirubin-albumin binding in human plasma","volume":"98","author":"Yu","year":"1999","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.jpba.2018.09.010_bib0240","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0090-9556(25)08642-8","article-title":"Influence of a single dose of ethanol on the kinetics of valproic acid in rats","volume":"18","author":"Alonso","year":"1990","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2018.09.010_bib0245","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0006-2952(93)90149-Q","article-title":"Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats","volume":"45","author":"Brouwer","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2018.09.010_bib0250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0090-9556(25)08283-2","article-title":"Disposition and protein binding of valproic acid in the developing rat","volume":"22","author":"Haberer","year":"1994","journal-title":"Drug Metab. Dispos."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518315607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518315607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T21:27:01Z","timestamp":1751837221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518315607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":50,"alternative-id":["S0731708518315607"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.09.010","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}